Participated · Equity · May 2025

Koppla, founded in 2020 by Jerome Lange, Marco Trippler, and Lasse Steffen, builds a scheduling and control platform for construction sites. Its software provides digital tools to plan, communicate, and track projects in real time, improving scheduling, communication, and collaboration among construction professionals. Koppla currently supports over 100 customers across 600 projects. The company will use the funds to further develop its scheduling and control platform and grow its customer base in the construction sector. It also plans to expand its team across customer success, sales, product, and technology. Koppla is based in Potsdam, Germany. koppla offers a digital platform that brings all contractors onto a single system to optimise and automate construction-site workflows from basement to loft. The company applies lean methodology to view the construction site as a production system and increase stability and efficiency across the building process. Founded in April 2020 at the Hasso‑Plattner‑Institute and based in Potsdam, koppla has deployed 20+ projects with German contractors including MBN, HABAU and Heitkamp, covering a project volume of over €500 million. With the new funding the startup plans to expand its technical offering and make key hires in both tech and sales. It is targeting the top 1,000 construction companies and real estate developers in the DACH region. Competition includes Munich’s Capmo and Berlin’s Cosuno, but koppla positions itself through its lean-driven approach and an evolving tech stack.

Participated · Seed · Jun 2024

Tacalyx focuses on discovery and development of antibodies against tumour associated carbohydrate antigens (TACAs) for cancer treatment. The company is developing modalities including antibody drug conjugates (ADCs) and other antibody-based therapies using a proprietary technology platform to exploit TACAs as targets. Its lead disclosed programme is TCX-201, an ADC directed at an undisclosed TACA, which the company plans to advance through preclinical development with proceeds from its recent financing. Tacalyx is expanding a differentiated pipeline of programmes built on its platform. The company is led by CEO Jean Engela and is headquartered in Berlin, Germany.

Participated · Equity · May 2024

Autovio provides a digital platform that centralizes organization, marketing, sales, billing and customer support for driving schools. The company says 50 driving schools currently use its infrastructure and about 3,000 learners have obtained their licenses through Autovio. Its stated goal is to make driving-school operations more efficient—raising the number of instructors per administrative staff from an industry average of roughly 2.5 to about 11. The platform also aims to improve the learner experience by enabling payments and appointment booking via smartphone, reducing bureaucracy and calls. The founders validate the concept in their own four-person driving school with daily reality checks. Autovio was founded in 2021 and is based in Berlin. The company recently completed a €3.8 million financing.

Participated · Equity · May 2024

Autovio digitizes the driving-school sector through mobile apps aimed at driving instructors and learners. The platform additionally offers services for marketing, sales, customer support and invoicing to driving schools. The company was founded by Tom Kedor, Philipp Goebel, Amir Hadi and Carsten Eckmiller. Autovio is headquartered in Berlin. The article reports a recent external investment of €3.8 million. No operating metrics were disclosed in the coverage.

Participated · Series B · Mar 2024

Protembis develops the ProtEmbo Cerebral Protection System, an intra-aortic filter delivered via the left radial artery to deflect embolic material away from cerebral arteries during transcatheter aortic valve replacement (TAVR) and other left-sided heart procedures. The company is advancing ProtEmbo through clinical investigations, including a pivotal FDA‑approved Investigational Device Exemption (IDE) study intended to enroll 250–500 patients in Europe and the US. Protembis is using recent financing to support clinical trials, research and development, and market access for the next‑generation device. Financially, the company completed a €30 million Series B in March 2024 and has secured an additional €20 million venture‑debt facility from the European Investment Bank. The EIB financing is supported by the InvestEU programme and is intended to accelerate product development and regulatory pathways. Protembis is a privately held emerging medtech based in Aachen, Germany. Protembis has developed the ProtEmbo® Cerebral Protection System, an intra-aortic filter device designed to protect the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). The low-profile, non-thrombogenic system shields all cerebral vessels and is delivered via the left radial artery to avoid interference with femoral-delivered TAVR equipment. The ProtEmbo System is currently undergoing clinical investigations, including the PROTEMBO IDE Pivotal Trial (NCT05873816). Protembis says its technology aims to reduce brain injury during left-sided heart procedures, improve patient quality of life, and lower healthcare costs associated with such injuries. The company is privately held and headquartered in Aachen, Germany. Recent financing activity is intended to support the ongoing pivotal trial and pre-commercial programs. Protembis has developed the ProtEmbo, a catheter-based filter advanced via the radial artery to cover arteries leading to the brain while allowing blood cells to pass and blocking embolic particles; the filter is heparin-coated to reduce clotting. The device is designed to minimize particle migration to the brain during transcatheter aortic valve implantation (TAVI/TAVR) and other interventional heart procedures. Protembis reported initial safety and feasibility and demonstrated effectiveness in a first-in-human clinical study. The company plans further clinical studies at leading heart centers in Europe and the U.S. and aims to bring the ProtEmbo to market maturity. Protembis emphasizes a large and growing market opportunity driven by demographic trends and increased use of minimally invasive heart valve interventions. The company has closed institutional backing via a recent Series A to fund development toward commercialization.